Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer research, 2023 - AACR
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …
被引用次数：54 相关文章
[HTML] nih.gov

[HTML][HTML] Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer …, 2023 - ncbi.nlm.nih.gov
Mutational loss of CDKN2A (encoding p16INK4A) tumor suppressor function is a key genetic
step that complements activation of KRAS in promoting the development and malignant …

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer Research, 2023 - AACR
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer …, 2023 - europepmc.org
Mutational loss of CDKN2A (encoding p16INK4A) tumor suppressor function is a key genetic
step that complements activation of KRAS in promoting the development and malignant …

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

CM Goodwin, AM Waters, JE Klomp… - Cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.

CM Goodwin, AM Waters, JE Klomp, S Javaid… - Cancer …, 2022 - europepmc.org
Mutational loss of CDKN2A (encoding p16INK4A) tumor suppressor function is a key genetic
step that complements activation of KRAS in promoting the development and malignant …